Who is eligible for a consultation?

Paxlovid or Molnupiravir are intended for those with mild to moderate COVID-19 who are at high-risk for progression to severe COVID-19, and who are within 5 days of symptom onset. Molnupiravir is only for patients for whom other COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. Learn more about Paxlovid on the manufacturer’s website, and review the patient and healthcare provider fact sheets for more information. Learn more about Molnupiravir on the manufacturer’s website, and review the patient and healthcare provider factsheets.

People who have had symptoms more than five days, who may be pregnant, or who are not at high risk for severe illness (based on age or medical history), may not be eligible for COVID-19 antiviral treatment through this program.

A consultation for COVID-19 antiviral treatment is currently only available through Color to those who are 18 or older. If you are under 18, please talk to a healthcare provider about treatment options.

Eligibility may also be restricted depending on your Color program sponsor’s terms. Eligibility through Color’s partnerships with Massachusetts, Washington, and Washington D.C. is limited to persons whose current address is in Massachusetts, Washington, and Washington D.C. and pharmacy products are only shipped to valid addresses in Massachusetts, Washington, and Washington D.C..

What treatment options for COVID-19 will be considered?

Clinicians will be evaluating whether a patient should be given a prescription for the COVID-19 antiviral treatments Paxlovid or Molnupiravir. If you are interested in other treatment options for COVID-19, please seek care from your healthcare provider.

What is Paxlovid?

Paxlovid has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.

If Paxlovid is appropriate, treatment should be initiated as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset. Paxlovid is not for people that have a history of allergy to nirmatrelvir or ritonavir or other components of these drugs, and it is not for people taking certain other drugs. Paxlovid may cause side effects, some of which may be serious and unexpected. Learn more about Paxlovid on the manufacturer’s website, at https://www.covid19oralrx-patient.com, and review the patient and healthcare provider fact sheets for more information.

The emergency use of Paxlovid is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization revoked sooner.

What is Molnupiravir?

Molnupiravir is authorized for emergency use by FDA under an EUA to treat mild-to-moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 including hospitalization or death, and for whom other COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Molnupiravir isn’t authorized for use in people less than 18 years of age, for prevention of COVID-19, for people needing hospitalization for COVID-19, or for use for longer than 5 consecutive days. Molnupiravir isn’t recommended for use in pregnancy as it may cause harm to an unborn baby. Molnupiravir may cause side effects, some of which may be serious and unexpected. Learn more about Molnupiravir on the manufacturer’s website and review the patient and healthcare provider fact sheets for more information.

The emergency use of Molnupiravir is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb3(b)(1), unless the declaration is terminated or authorization revoked sooner.

Trademarks referenced herein held by their respective owners.

Will I have to pay for the consultation or COVID-19 antiviral treatment?

No. The Color services, including clinical consultation and mail order pharmacy service, are made available at no cost to you. The cost of Paxlovid or Molnupiravir is currently covered by the federal government (subject to change).

If you choose to use a local pharmacy, you are responsible if there are any associated costs.

Did this answer your question?